The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study
Sibel Cakir, Isin Baral KulaksizogluIstanbul University, Istanbul Medical School, Psychiatry Department, Geropsychiatry Unit, Istanbul, TurkeyAbstract: Agitation is one of the most devastating behavioral symptoms in demented patients but there is little evidence about effective and safe pharmacother...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d22150e1f92b4c6193e074ebd0475a32 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d22150e1f92b4c6193e074ebd0475a32 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d22150e1f92b4c6193e074ebd0475a322021-12-02T00:24:09ZThe efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study1176-63281178-2021https://doaj.org/article/d22150e1f92b4c6193e074ebd0475a322008-09-01T00:00:00Zhttp://www.dovepress.com/the-efficacy-of-mirtazapine-in-agitated-patients-with-alzheimerrsquos--a2258https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Sibel Cakir, Isin Baral KulaksizogluIstanbul University, Istanbul Medical School, Psychiatry Department, Geropsychiatry Unit, Istanbul, TurkeyAbstract: Agitation is one of the most devastating behavioral symptoms in demented patients but there is little evidence about effective and safe pharmacotherapy. We aimed to determine the effectiveness and safety of mirtazapine in treatment of agitated patients with Alzheimer’s disease (AD). The consecutive patients with AD who have significant agitation were assigned to a 12-week open-label, prospective study. Patients received mirtazapine 15–30 mg/day. The changes in Cohen-Mansfi eld Agitation Inventory-Short form (CMAI-SF) scores were primary outcome measurement. The change in Clinical Global Impression-Severity scale (CGI-S) scores and tolerability-safety profile were the secondary efficacy variables. Thirteen of 16 (81.25%) patients completed the study. There was a significant reduction in CMAI-SF and CGI-S between the pre- and post-treatment with mirtzapaine (p < 0.001). The mean baseline score was 26.54 (±5.4) and mean reduction was 10.6 (±7.5) in CMAI-SF. There was no significant side effect and cognitive deterioration. The results of this open-label pilot study suggest that mirtazapine may be an effective choice for treatment of agitated patients with AD.Keywords: agitation, Alzheimer’s disease, treatment, mirtazapine, safety, open-label Sibel CakirIsin Baral KulaksizogluDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 5, Pp 963-966 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Sibel Cakir Isin Baral Kulaksizoglu The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study |
| description |
Sibel Cakir, Isin Baral KulaksizogluIstanbul University, Istanbul Medical School, Psychiatry Department, Geropsychiatry Unit, Istanbul, TurkeyAbstract: Agitation is one of the most devastating behavioral symptoms in demented patients but there is little evidence about effective and safe pharmacotherapy. We aimed to determine the effectiveness and safety of mirtazapine in treatment of agitated patients with Alzheimer’s disease (AD). The consecutive patients with AD who have significant agitation were assigned to a 12-week open-label, prospective study. Patients received mirtazapine 15–30 mg/day. The changes in Cohen-Mansfi eld Agitation Inventory-Short form (CMAI-SF) scores were primary outcome measurement. The change in Clinical Global Impression-Severity scale (CGI-S) scores and tolerability-safety profile were the secondary efficacy variables. Thirteen of 16 (81.25%) patients completed the study. There was a significant reduction in CMAI-SF and CGI-S between the pre- and post-treatment with mirtzapaine (p < 0.001). The mean baseline score was 26.54 (±5.4) and mean reduction was 10.6 (±7.5) in CMAI-SF. There was no significant side effect and cognitive deterioration. The results of this open-label pilot study suggest that mirtazapine may be an effective choice for treatment of agitated patients with AD.Keywords: agitation, Alzheimer’s disease, treatment, mirtazapine, safety, open-label |
| format |
article |
| author |
Sibel Cakir Isin Baral Kulaksizoglu |
| author_facet |
Sibel Cakir Isin Baral Kulaksizoglu |
| author_sort |
Sibel Cakir |
| title |
The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study |
| title_short |
The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study |
| title_full |
The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study |
| title_fullStr |
The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study |
| title_full_unstemmed |
The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study |
| title_sort |
efficacy of mirtazapine in agitated patients with alzheimer’s disease: a 12-week open-label pilot study |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/d22150e1f92b4c6193e074ebd0475a32 |
| work_keys_str_mv |
AT sibelcakir theefficacyofmirtazapineinagitatedpatientswithalzheimeramprsquosdiseasea12weekopenlabelpilotstudy AT isinbaralkulaksizoglu theefficacyofmirtazapineinagitatedpatientswithalzheimeramprsquosdiseasea12weekopenlabelpilotstudy AT sibelcakir efficacyofmirtazapineinagitatedpatientswithalzheimeramprsquosdiseasea12weekopenlabelpilotstudy AT isinbaralkulaksizoglu efficacyofmirtazapineinagitatedpatientswithalzheimeramprsquosdiseasea12weekopenlabelpilotstudy |
| _version_ |
1718403770040188928 |